| Stock Market | NYSE Euronext Paris - Eurolist (compartment B) |
| Reuters /Bloomberg | TRNG.PA / TNG.FP |
| ISIN Code | FR0005175080 |
| Total number of shares outstanding | 31 662 075 |
| First Quote on Nouveau Marché & Nasdaq* | 26 March 1998 |
| Local Sector Index | Next Biotech / CAC Mid 100 |
| Financial Year Ends | December 31 |
*De-listed from Nasdaq in September 2005
Funding History
| Date | Operation | Capital Raised |
| June 2010 |
Capital Increase |
€152.0 million |
| June 2007 |
Capital Increase |
€100.1 million |
| July 2006 |
Capital Increase/Warrants Exercised |
€14.3 million |
| June 2005 | Capital Increase on Euronext Paris |
€34.9 million |
| May 2001 |
Follow-on Nouveau Marché & Nasdaq |
US$54 million |
| March 1998 |
IPO Nouveau Marché & Nasdaq | US$100 million |
Shareholding Structure
 |
|
Key Financial Highlights (€ Million)
| Year | Cash Burn (net) | R&D expenditure | Cash & cash equivalents |
| 2009 | 22.0 | 33.0 | 64.7 |
| 2008 | 24.6 |
32.3 |
86.7 |
| 2007 |
5.5* | 28.8 |
111.3 |
| 2006 |
20.6 |
24.2 |
20.3 |
| 2005 | 20.7 | 20.9 | 26.5 |
* Includes €23m received from Roche